1. Home
  2. IKT vs USAU Comparison

IKT vs USAU Comparison

Compare IKT & USAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$2.46

Market Cap

220.5M

Sector

Health Care

ML Signal

N/A

Logo U.S. Gold Corp.

USAU

U.S. Gold Corp.

N/A

Current Price

$15.16

Market Cap

214.2M

ML Signal

N/A

Company Overview

Basic Information
Metric
IKT
USAU
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precious Metals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
220.5M
214.2M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
IKT
USAU
Price
$2.46
$15.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$5.00
$22.83
AVG Volume (30 Days)
960.3K
231.7K
Earning Date
03-26-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
57.76
36.11
EPS
N/A
N/A
Revenue
N/A
$17,402,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$10.32
52 Week High
$2.53
$23.72

Technical Indicators

Market Signals
Indicator
IKT
USAU
Relative Strength Index (RSI) 68.09 55.47
Support Level $1.63 $14.15
Resistance Level $2.53 $16.50
Average True Range (ATR) 0.14 0.72
MACD 0.01 0.26
Stochastic Oscillator 92.68 78.93

Price Performance

Historical Comparison
IKT
USAU

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

About USAU U.S. Gold Corp.

U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.

Share on Social Networks: